phrykt

SAB Biotherapeutics, Inc. (SABS): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of SABS were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling SAB Biotherapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SABS

87 funds and institutions reported SABS shares worth $267M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Caligan Partners LP with 15.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Caligan Partners LP15.6%
Vivo Capital, LLC14.3%
Perceptive Advisors LLC13.0%
Adage Capital Partners Gp, L.l.c.12.6%
Ra Capital Management, L.P.8.6%
Balyasny Asset Management L.P.7.4%
BlackRock, Inc.6.0%
Vanguard Capital Management LLC5.8%
Commodore Capital LP5.6%
Millennium Management LLC5.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Caligan Partners LP7.97M15.64%$31.1MNo change
Vivo Capital, LLC7.30M14.33%$28.5M-36%
Perceptive Advisors LLC6.63M13.01%$25.8M+3%
Adage Capital Partners Gp, L.l.c.6.41M12.57%$25M+88%
Ra Capital Management, L.P.4.40M8.64%$17.2MNo change
Balyasny Asset Management L.P.3.76M7.38%$14.7MNo change
BlackRock, Inc.3.07M6.02%$12M+918%
Vanguard Capital Management LLC2.97M5.83%$11.6M+19%
Commodore Capital LP2.87M5.63%$11.2M-35%
Millennium Management LLC2.75M5.40%$10.7M-9%
Spruce Street Capital LP2.20M4.31%$8.6MNo change
Sessa Capital IM, L.P.2.20M4.31%$8.6MNo change
Affinity Asset Advisors, LLC1.52M2.99%$5.9M+165%
Boothbay Fund Management, LLC1.48M2.91%$5.8MNo change
Geode Capital Management, LLC1.28M2.51%$5M+323%
Woodline Partners LP1.18M2.32%$4.6M-59%
Ensign Peak Advisors, Inc1.17M2.30%$4.6M-15%
Propel Bio Management, LLC1.08M2.11%$4.2M+6%
Soleus Capital Management, L.P.900,0001.77%$3.5M-14%
Seven Fleet Capital Management LP736,0771.44%$2.9M+636%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No SABS insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SABS short interest

Moderate short interest. 5.5% of SABS shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went up 83%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.03M SABS shares were sold short, 5.5% of the shares outstanding, up 4.7% from the report before. At the average daily volume of 606,985 shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

5.52%May 15Oct 309.93%

Days to cover

8.3May 15Oct 3015.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.03M5.52%+5%606,9858.3
Oct 15, 20264.80M5.28%+12%692,9606.9
Sep 30, 20264.29M4.72%+19%860,6425.0
Sep 15, 20263.60M3.96%-13%269,53313.4
Aug 31, 20264.12M4.53%-11%326,70712.6
Aug 14, 20264.63M5.09%-1%420,78411.0
Jul 31, 20264.66M9.15%+6%520,5818.9
Jul 15, 20264.38M8.59%+16%464,5519.4
Jun 30, 20263.77M7.41%+31%1.40M2.7
Jun 15, 20262.88M5.65%+9%851,5623.4
May 29, 20262.64M5.19%-4%396,2486.7
May 15, 20262.75M5.39%+14%1.56M1.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

SAB Biotherapeutics company events

SAB Biotherapeutics filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 13, 2026.

  1. Oct 13, 2026AnnouncementSAB Biotherapeutics, Inc., a Delaware corporation, issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy being developed for the treatment of individuals with new-onset Stage 3 type 1… Filing
  2. Jul 7, 2026AnnouncementShared information with investors. Filing
  3. Jun 18, 2026VoteReported shareholder vote results. Filing
  4. May 4, 2026AgreementSAB Biotherapeutics, Inc., a Delaware corporation entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. Filing
  5. Apr 22, 2026AnnouncementShared information with investors. Filing
  6. Mar 19, 2026AgreementSAB Biotherapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. as the representatives of the several underwriters named therein, relating to an underwritten offering of (i) 19,324,677 shares of the… Filing
  7. Mar 10, 2026AnnouncementThe Company announced additional data from its Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. Filing
  8. Jan 12, 2026AnnouncementShared information with investors. Filing
  9. Jan 7, 2026LeadershipThe Board of Directors of SAB Biotherapeutics, Inc., a Delaware corporation, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed, David Zaccardelli, Pharm.D, and Rita Jain, M.D. each to serve as a Class II director of the Company, effective… Filing
  10. Dec 29, 2025AnnouncementSAB Biotherapeutics, Inc. entered into a Sales Agreement (the “ Agreement ” ) with UBS Securities LLC with respect to an at-the-market offering program under which the Company may offer and sell from time to time through or to the Agent, as sales agent or principal, the Company’s common stock, par… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

SAB Biotherapeutics financials

Famous investors that hold SABS

3 of the 50 well-known investors we track reported holding SABS in their latest 13F filing. The largest position is Israel Englander's, worth $10.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.45M$10.9M0.0%+26%
Ken Griffin · Citadel AdvisorsQ3 2026126,560$401K0.0%+102%
Jim Simons · Renaissance TechnologiesQ3 202643,800$139K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named SABS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A7.9%
Nov 16, 2026Woodline Partners LP13G/A5.7%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A7.9%
Nov 16, 2026Vivo Opportunity Fund Holdings, L.P.13G/A10.0%
Nov 16, 2026Vivo Opportunity Fund Holdings, L.P.13G/A10.0%
Nov 16, 2026Woodline Partners LP13G/A5.7%

Questions about SAB Biotherapeutics, Inc. (SABS) stock

Who owns the most SABS stock?

The largest reported owner of SAB Biotherapeutics, Inc. (SABS) is Caligan Partners LP, with 15.6% of the company. In total, 87 funds and institutions reported holding SABS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SABS insiders buying or selling?

No SABS insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in SABS?

As of Oct 30, 2026, 5.03M SABS shares were sold short, 5.5% of the shares outstanding, up 4.7% from the report before. At the average daily volume of 606,985 shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold SABS?

3 of the 50 well-known investors we track reported SABS in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $10.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.